Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 ( PALACE 1 ) compared apremilast with placebo in patients with active psoriatic arthritis despite prior traditional disease-modifying antirheumatic drug ( DMARD ) and/or biologic therapy .